Literature DB >> 24503021

Treatment with Saccharomyces boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice.

Priscilla F C Justino1, Luis F M Melo1, Andre F Nogueira1, Jose V G Costa1, Luara M N Silva1, Cecila M Santos1, Walber O Mendes1, Marina R Costa1, Alvaro X Franco1, Aldo A Lima1, Ronaldo A Ribeiro1, Marcellus H L P Souza1, Pedro M G Soares1.   

Abstract

Intestinal mucositis is an important toxic side effect of 5-fluorouracil (5-FU) treatment. Saccharomyces boulardii is known to protect from intestinal injury via an effect on the gastrointestinal microbiota. The objective of the present study was to evaluate the effect of S. boulardii on intestinal mucositis induced by 5-FU in a murine model. Mice were divided into saline, saline (control)+5-FU or 5-FU+S. boulardii (16 × 10⁹ colony-forming units/kg) treatment groups, and the jejunum and ileum were removed after killing of mice for the evaluation of histopathology, myeloperoxidase (MPO) activity, and non-protein sulfhydryl group (mainly reduced glutathione; GSH), nitrite and cytokine concentrations. To determine gastric emptying, phenol red was administered orally, mice were killed 20 min after administration, and the absorbance of samples collected from the mice was measured by spectrophotometry. Intestinal permeability was measured by the urinary excretion rate of lactulose and mannitol following oral administration. S. boulardii significantly reversed the histopathological changes in intestinal mucositis induced by 5-FU and reduced the inflammatory parameters: neutrophil infiltration (control 1·73 (SEM 0·37) ultrastructural MPO (UMPO)/mg, 5-FU 7·37 (SEM 1·77) UMPO/mg and 5-FU+S. boulardii 4·15 (SEM 0·73) UMPO/mg); nitrite concentration (control 37·00 (SEM 2·39) μm, 5-FU 59·04 (SEM 11·41) μm and 5-FU+S. boulardii 37·90 (SEM 5·78) μm); GSH concentration (control 477·60 (SEM 25·25) μg/mg, 5-FU 270·90 (SEM 38·50) μg/mg and 5-FU+S. boulardii 514·00 (SEM 38·64) μg/mg). Treatment with S. Boulardii significantly reduced the concentrations of TNF-α and IL-1β by 48·92 and 32·21 % in the jejunum and 38·92 and 61·79 % in the ileum. In addition, S. boulardii decreased the concentrations of chemokine (C-X-C motif) ligand 1 by 5-fold in the jejunum and 3-fold in the ileum. Interestingly, S. boulardii reduced the delay in gastric emptying (control 25·21 (SEM 2·55) %, 5-FU 54·91 (SEM 3·43) % and 5-FU+S. boulardii 31·38 (SEM 2·80) %) and induced the recovery of intestinal permeability (lactulose:mannitol ratio: control 0·52 (SEM 0·03), 5-FU 1·38 (SEM 0·24) and 5-FU+S. boulardii 0·62 (SEM 0·03)). In conclusion, S. boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in intestinal mucositis induced by 5-FU.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24503021     DOI: 10.1017/S0007114513004248

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  27 in total

Review 1.  Ecological Therapeutic Opportunities for Oral Diseases.

Authors:  Anilei Hoare; Philip D Marsh; Patricia I Diaz
Journal:  Microbiol Spectr       Date:  2017-08

Review 2.  Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.

Authors:  Lauren E Hudson; Sarah E Anderson; Anita H Corbett; Tracey J Lamb
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 3.  Application of vitamin-producing lactic acid bacteria to treat intestinal inflammatory diseases.

Authors:  Jean Guy LeBlanc; Alejandra de Moreno de LeBlanc; Romina Levit; Graciela Savoy de Giori
Journal:  Appl Microbiol Biotechnol       Date:  2020-02-28       Impact factor: 4.813

Review 4.  The pathogenesis of mucositis: updated perspectives and emerging targets.

Authors:  J Bowen; N Al-Dasooqi; P Bossi; H Wardill; Y Van Sebille; A Al-Azri; E Bateman; M E Correa; J Raber-Durlacher; A Kandwal; B Mayo; R G Nair; A Stringer; K Ten Bohmer; D Thorpe; R V Lalla; S Sonis; K Cheng; S Elad
Journal:  Support Care Cancer       Date:  2019-07-08       Impact factor: 3.603

5.  Anti-inflammatory effect of L-cysteine (a semi-essential amino acid) on 5-FU-induced oral mucositis in hamsters.

Authors:  Khetyma Moreira Fonseca; Dionys Macda RodriguesCosta; Valderlon Freitas da Silva; Jelson Lina de Carvalho; Ana Patrícia Oliveira; Francisca Beatriz de Melo Sousa; André Luis Fernandes Lopes; Conceição da Silva Martins; Letícia de Sousa Chaves; Lucas Antonio Duarte Nicolau; Gilberto Santos Cerqueira; Jand Venes Rolim Medeiros
Journal:  Amino Acids       Date:  2021-08-19       Impact factor: 3.520

6.  Moxibustion attenuates inflammation in intestinal mucosal by regulating RAGE-mediated TLR4-NF-κBp65 signaling pathway in vivo and in vitro.

Authors:  Bingrong Li; Long Yuan; Peng Liu; Zixiang Geng; Kaiyong Zhang; Huiru Jiang; Hua Sui; Bimeng Zhang
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

7.  Metformin inhibited colitis and colitis-associated cancer (CAC) through protecting mitochondrial structures of colorectal epithelial cells in mice.

Authors:  Shu-Qing Wang; Shu-Xiang Cui; Xian-Jun Qu
Journal:  Cancer Biol Ther       Date:  2018-10-25       Impact factor: 4.742

8.  The Microbiome and Cancer: Is the 'Oncobiome' Mirage Real?

Authors:  Ryan M Thomas; Christian Jobin
Journal:  Trends Cancer       Date:  2015-09-01

9.  Alanyl-glutamine attenuates 5-fluorouracil-induced intestinal mucositis in apolipoprotein E-deficient mice.

Authors:  C V Araújo; C R Lazzarotto; C C Aquino; I L Figueiredo; T B Costa; L A de Oliveira Alves; R A Ribeiro; L R Bertolini; A A M Lima; G A C Brito; R B Oriá
Journal:  Braz J Med Biol Res       Date:  2015-04-28       Impact factor: 2.590

10.  Antarctic Strain of Rhodotorula mucilaginosa UFMGCB 18,377 Attenuates Mucositis Induced by 5-Fluorouracil in Mice.

Authors:  Joana O P A Coutinho; Mônica F Quintanilha; Marina R A Campos; Enio Ferreira; Graciéle C A de Menezes; Luiz H Rosa; Carlos A Rosa; Katia D Vital; Simone O A Fernandes; Valbert N Cardoso; Jacques R Nicoli; Fabiana C P Tiago; Flaviano S Martins
Journal:  Probiotics Antimicrob Proteins       Date:  2021-07-13       Impact factor: 5.265

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.